< Back to previous page
Researcher
Ignace Vergote
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Jan 2012 → Today
Projects
1 - 10 of 12
- Exploring the heterogeneity of rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → 1 Apr 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
- Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach.From1 Aug 2019 → 11 Oct 2023Funding: FWO Strategic Basic Research Grant
- Comprehensive genomic and transcriptomic analysis of high grade serous ovarian cancer using single-cell RNA-sequencing.From1 Jan 2019 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
- Searching for new leads in the diagnosis of ovarian cancerFrom1 Oct 2017 → 30 Sep 2021Funding: Foundations, funds and other with scientific goal
- Comprehensive transcriptomic analysis of high-grade serous tubo-ovarian carcinoma using single-cell RNA-sequencing.From1 Mar 2017 → 5 Jul 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- From Never to Always Events: in search for mango-momentsFrom1 Nov 2016 → 31 Oct 2018Funding: Nonprofit institution or equivalents
- FIRST PET-MR: Flmeish interuniversity research simultaneous time-of-flight PET-MR scanner.From14 Aug 2014 → 13 Feb 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Flemish interuniversity simultaneous time-of-flight PET-MR scanner for research.From14 Aug 2014 → 13 Feb 2019Funding: Hercules - Large scale research infrastructure
- A drug strategy targeting stabilised mutant p53 to fight metastatic plantinum-resistant ovarian cancer.From1 Oct 2013 → 31 Mar 2019Funding: General Activities (Annex IV)
- Dendritic cell immunotherapy in serous ovarian cancer.From1 Oct 2013 → 30 Sep 2016Funding: FWO fellowships
Publications
11 - 20 of 773
- GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles(2023)
Authors: Ignace Vergote
- Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer(2023)
Authors: Toon Van Gorp, Ignace Vergote
Pages: 5400 - + - Selinexor in patients with advanced and recurrent endometrial cancer(2023)
Authors: Ignace Vergote
- Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ ENGOT-ov38): a phase IIIb trial(2023)
Authors: Ignace Vergote
Pages: 1152 - 1164 - Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial(2023)
Authors: Ignace Vergote
Pages: 3556 - 3563 - Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994(2023)
Authors: Ignace Vergote
Pages: 5035 - + - Clonal Hematopoiesis in Whole-Blood and Cell-Free DNA of Ovarian Cancer Patients Undergoing PARP-Inhibitor Treatment: An Exploratory Analysis of the ENGOTov48/Eudario Trial(2023)
Authors: Ignace Vergote
- New FIGO 2023 endometrial cancer staging validation. Welcome to the first molecular classifiers and new pathological variables!(2023)
Authors: Ignace Vergote
- Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey(2023)
Authors: Ignace Vergote
- InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer(2023)
Authors: Els Van Nieuwenhuysen, Ignace Vergote
Pages: S1586 - S1586
Patents
1 - 1 of 1
- Methods for diagnosing ovarian cancer (Inventor)